HealthCor
View Older Stories View More Recent Stories
-
Form 13F-HR HealthCor Partners Manag For: Sep 30
-
Form 4 Heartflow, Inc. For: Aug 11 Filed by: HealthCor Partners Fund II, L.P.
-
Form 3 Heartflow, Inc. For: Aug 07 Filed by: HealthCor Partners Fund II, L.P.
-
OceanSound Partners Adds Seven New Professionals to its Growing Team
-
CareView Communications Converts Secured Debt for Projected Growth
-
Form 4 CareView Communications For: May 24 Filed by: HealthCor Partners LP
-
Form 4 CareView Communications For: May 24 Filed by: HealthCor Management, L.P.
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Cutera (CUTR) Announces Agreements with Pura Vida and RTW
-
Cutera Announces Agreements with Pura Vida and RTW
-
Bryn Pharma Expands Corporate Leadership with Three New Executive Hires and Additional Board Appointment
-
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
-
HeartFlow, Leader in Revolutionizing Precision Heart Care, Closes $215 Million in Series F Funding Led by Bain Capital Life Sciences
-
Form 4 CareView Communications For: Mar 30 Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Mar 30 Filed by: HealthCor Partners LP
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Form 13F-HR HealthCor Management, For: Dec 31
-
Form SC 13G/A Research Alliance Corp. Filed by: HealthCor Management, L.P.
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Dec 30 Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Dec 30 Filed by: HealthCor Partners LP
-
Catalio Capital Management Launches Long-Short Public Equities Strategy Focused on Global Healthcare and Life Sciences Sectors
-
Karyopharm Therapeutics (KPTI) Announces $165 Million Private Placement
-
Karyopharm Announces $165 Million Private Placement
-
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
-
Form 13F-HR HealthCor Management, For: Sep 30
-
Form 13F-HR HealthCor Management, For: Jun 30
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Jun 30 Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Jun 30 Filed by: HealthCor Partners LP
-
Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directors
-
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension
-
Outcome of Innate Pharma’s 2022 Annual General Meeting
-
Form 13F-HR HealthCor Management, For: Mar 31
-
Form 4 CareView Communications For: Mar 31 Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Mar 31 Filed by: HealthCor Partners LP
-
Form D HealthCor Therapeutics,
-
Form D HealthCor Therapeutics
-
Form D HealthCor Co-Invest Sana
-
Form D HEALTHCOR OFFSHORE LTD
-
Form D HealthCor Sanatate Offsh
-
Form D HEALTHCOR HYBRID OFFSHOR
-
Form 4 CareView Communications For: Mar 08 Filed by: HealthCor Management, L.P.
-
Form 4 CareView Communications For: Mar 08 Filed by: HealthCor Partners LP
-
Form SC 13D/A CareView Communications Filed by: HealthCor Management, L.P.
-
Form D HEALTHCOR L P
-
Form 13F-HR HealthCor Management, For: Dec 31
-
Form SC 13G/A Research Alliance Corp. Filed by: HealthCor Management, L.P.
-
Form SC 13G/A Medicus Sciences Acquisi Filed by: HealthCor Management, L.P.

